{
    "info": {
        "nct_id": "NCT04401774",
        "official_title": "Phase II Maintenance Trial of Nivolumab for Newly Diagnosed PCNSL Patients With Persistent Circulating Tumor DNA in the CSF After Completion of Methotrexate-Based First-Line Induction Chemotherapy",
        "inclusion_criteria": "Biospecimen and Data Collection:\n\n* Histologically documented PCNSL with the ability to submit up to 20 unstained formalinfixed, paraffin embedded (FFPE) slides from the initial tissue diagnosis prior to study registration or histologically confirmed lymphomatous involvement of the CSF and/or eye/vitreous\n* Patients must be able to tolerate MRI/CT scans with [18F FDG]\n* Patients must be able to tolerate lumbar punctures and/or Ommaya taps\n\nAdditional Criteria for Nivolumab Maintenance Arm:\n\nAll criteria in the above \"Biospecimen and Data Collection\" section must be satisfied as well as:\n\n* Persistent cfDNA in the CSF\n* Participants must be able to understand and be willing to sign a written informed consent document\n* Women and men who are at least 18 years of age on the day of consenting to the study\n* KPS ≥60\n* Life expectancy of > 3 months (in the opinion of the investigator)\n* Participants must have adequate bone marrow and organ function shown by:\n\n  * Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L\n  * Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration\n  * Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration\n  * International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal. Patients on anticoagulants should be managed according to MSK SOPs as outlined in: 'Therapeutic Anticoagulation Guidelines in Adults' regarding management of anticoagulants prior to each CSF collection. Please discuss any complicated patient with the PI for consideration.\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal\n  * Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome\n  * Serum creatinine ≤ 2 times the upper limit of normal\n* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 5 months after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 7 months after the last dose\n* Women of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Biospecimen and Data Collection:\n\n* Patients with recurrent/refractory PCNSL. Patients with stable disease as their best response to first-line chemotherapy will also come off study.\n* Patient with systemic, non-CNS lymphoma metastatic to the CNS\n* Patient is known to have human immunodeficiency virus (HIV) infection\n* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests\n* Patient's who are planned to undergo consolidation with autologous HSCT\n\nAdditional Criteria for Nivolumab Maintenance Arm:\n\nNone of the criteria in the above \"Biospecimen and Data Collection\" section can be present. The following criteria must also not be present:\n\n* Patient has undergone prior allogenic stem cell transplant\n* Patient's who are planned to undergo consolidation with autologous HSCT\n* Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 14 days of the first dose of study drug\n* Patient is allergic to components of the study drug\n* Patient is concurrently using other approved or investigational antineoplastic agents\n* Previous or current treatment with an anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PDL2 agent\n* Patient has an active concurrent malignancy requiring active therapy\n* Patient is requiring escalating or chronic supraphysiologic doses of corticosteroids (> 8 mg dexamethasone daily) for control of disease at the time of registration\n* Patient is using systemic immunosuppressant therapy including: cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day of prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Known history of, or any evidence of active, non-infectious pneumonitis\n* Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, uncontrolled congestive heart failure, uncontrolled hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening\n* Peptic ulcer, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past 6 months\n* Patient is known to have an uncontrolled active systemic infection\n* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk\n* Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive plasma hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and Reproduction)\n* The patient is unwell or unable to participate in all required study evaluations and procedures\n* Participants who have received a live / attenuated vaccine within 30 days of first treatment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 times the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must have a negative plasma pregnancy test upon study entry",
                    "criterion": "plasma pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "upon study entry"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤ 1.5 times the upper limit of normal",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "patient has well documented Gilbert Syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin within the normal range in patients with well documented Gilbert Syndrome",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within the normal range"
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "patient has well documented Gilbert Syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate MRI/CT scans with [18F FDG]",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to tolerate MRI/CT scans with [18F FDG]",
                    "criterion": "tolerance to MRI/CT scans with [18F FDG]",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤ 2 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2 times the upper limit of normal",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented PCNSL with the ability to submit up to 20 unstained formalinfixed, paraffin embedded (FFPE) slides from the initial tissue diagnosis prior to study registration or histologically confirmed lymphomatous involvement of the CSF and/or eye/vitreous",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented PCNSL",
                    "criterion": "PCNSL (primary central nervous system lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to submit up to 20 unstained formalinfixed, paraffin embedded (FFPE) slides from the initial tissue diagnosis prior to study registration",
                    "criterion": "FFPE slides from initial tissue diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "availability for submission",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "maximum number",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "slides"
                            }
                        },
                        {
                            "requirement_type": "unstained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "formalin-fixed, paraffin embedded",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically confirmed lymphomatous involvement of the CSF and/or eye/vitreous",
                    "criterion": "lymphomatous involvement of the CSF and/or eye/vitreous",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have adequate bone marrow and organ function shown by:",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow and organ function",
                    "criterion": "bone marrow and organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 5 months after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 7 months after the last dose",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 5 months after the last dose of the study drug.",
                    "criterion": "contraception use (women of reproductive potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 7 months after the last dose",
                    "criterion": "contraception use (sexually active men)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of therapy"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 7,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 75 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no platelet transfusion within the past 21 days prior to study registration",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within past 21 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to tolerate lumbar punctures and/or Ommaya taps",
            "criterions": [
                {
                    "exact_snippets": "able to tolerate lumbar punctures",
                    "criterion": "tolerance of lumbar punctures",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to tolerate ... Ommaya taps",
                    "criterion": "tolerance of Ommaya taps",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* KPS ≥60",
            "criterions": [
                {
                    "exact_snippets": "KPS ≥60",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal. Patients on anticoagulants should be managed according to MSK SOPs as outlined in: 'Therapeutic Anticoagulation Guidelines in Adults' regarding management of anticoagulants prior to each CSF collection. Please discuss any complicated patient with the PI for consideration.",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) ≤ 1.5",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT (aPTT) ≤ 1.5 times the upper limit of normal",
                    "criterion": "PTT (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "All criteria in the above \"Biospecimen and Data Collection\" section must be satisfied as well as:",
            "criterions": [
                {
                    "exact_snippets": "All criteria in the above \"Biospecimen and Data Collection\" section must be satisfied",
                    "criterion": "criteria in the \"Biospecimen and Data Collection\" section",
                    "requirements": [
                        {
                            "requirement_type": "satisfaction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Persistent cfDNA in the CSF",
            "criterions": [
                {
                    "exact_snippets": "Persistent cfDNA in the CSF",
                    "criterion": "cfDNA in the CSF",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Biospecimen and Data Collection:",
            "criterions": [
                {
                    "exact_snippets": "Biospecimen ... Collection",
                    "criterion": "biospecimen",
                    "requirements": [
                        {
                            "requirement_type": "collection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Data ... Collection",
                    "criterion": "data",
                    "requirements": [
                        {
                            "requirement_type": "collection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of > 3 months (in the opinion of the investigator)",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of > 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(in the opinion of the investigator)",
                    "criterion": "investigator opinion on life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women and men who are at least 18 years of age on the day of consenting to the study",
            "criterions": [
                {
                    "exact_snippets": "Women and men",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "female",
                                "male"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on the day of consenting to the study",
                    "criterion": "age at consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "on the day of consenting to the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Criteria for Nivolumab Maintenance Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nivolumab Maintenance Arm",
                    "criterion": "treatment arm",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "Nivolumab Maintenance Arm"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥ 8 g/dL",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no red blood cell (RBC) transfusion within the past 21 days prior to study registration",
                    "criterion": "red blood cell (RBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 21 days prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be able to understand and be willing to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Participants must be able to understand ... sign a written informed consent document",
                    "criterion": "ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patient with systemic, non-CNS lymphoma metastatic to the CNS",
            "criterions": [
                {
                    "exact_snippets": "systemic, non-CNS lymphoma",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "systemic"
                        },
                        {
                            "requirement_type": "exclusion_location",
                            "expected_value": "CNS"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic to the CNS",
                    "criterion": "lymphoma metastasis",
                    "requirements": [
                        {
                            "requirement_type": "metastatic_site",
                            "expected_value": "CNS"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Biospecimen and Data Collection:",
            "criterions": [
                {
                    "exact_snippets": "Biospecimen ... Collection",
                    "criterion": "biospecimen",
                    "requirements": [
                        {
                            "requirement_type": "collection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Data ... Collection",
                    "criterion": "data",
                    "requirements": [
                        {
                            "requirement_type": "collection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 14 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Any chemotherapy ... within 14 days of the first dose of study drug",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "external beam radiation therapy ... within 14 days of the first dose of study drug",
                    "criterion": "external beam radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticancer antibodies within 14 days of the first dose of study drug",
                    "criterion": "anticancer antibodies",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is concurrently using other approved or investigational antineoplastic agents",
            "criterions": [
                {
                    "exact_snippets": "concurrently using other approved or investigational antineoplastic agents",
                    "criterion": "use of other antineoplastic agents",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "approved",
                                "investigational"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have human immunodeficiency virus (HIV) infection",
            "criterions": [
                {
                    "exact_snippets": "Patient is known to have human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, uncontrolled congestive heart failure, uncontrolled hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening",
            "criterions": [
                {
                    "exact_snippets": "significant abnormalities on screening electrocardiogram (EKG)",
                    "criterion": "screening electrocardiogram (EKG) abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled or symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pericarditis",
                    "criterion": "pericarditis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within 6 months of screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peptic ulcer, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past 6 months",
            "criterions": [
                {
                    "exact_snippets": "Peptic ulcer ... within past 6 months",
                    "criterion": "peptic ulcer",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "abdominal fistula ... within past 6 months",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal perforation ... within past 6 months",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "intra-abdominal abscess within past 6 months",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is using systemic immunosuppressant therapy including: cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day of prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug",
            "criterions": [
                {
                    "exact_snippets": "Patient is using systemic immunosuppressant therapy including: cyclosporine A, tacrolimus, sirolimus, and other such medications",
                    "criterion": "systemic immunosuppressant therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic administration of > 5 mg/day of prednisone or the equivalent",
                    "criterion": "prednisone or equivalent corticosteroid administration",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug",
                    "criterion": "immunosuppressant therapy",
                    "requirements": [
                        {
                            "requirement_type": "off therapy duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of, or any evidence of active, non-infectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Known history of, or any evidence of active, non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is requiring escalating or chronic supraphysiologic doses of corticosteroids (> 8 mg dexamethasone daily) for control of disease at the time of registration",
            "criterions": [
                {
                    "exact_snippets": "requiring escalating or chronic supraphysiologic doses of corticosteroids (> 8 mg dexamethasone daily) for control of disease at the time of registration",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "mg dexamethasone daily"
                            }
                        },
                        {
                            "requirement_type": "pattern",
                            "expected_value": [
                                "escalating",
                                "chronic supraphysiologic"
                            ]
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "for control of disease"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has undergone prior allogenic stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "undergone prior allogenic stem cell transplant",
                    "criterion": "prior allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "None of the criteria in the above \"Biospecimen and Data Collection\" section can be present. The following criteria must also not be present:",
            "criterions": [
                {
                    "exact_snippets": "None of the criteria in the above \"Biospecimen and Data Collection\" section can be present.",
                    "criterion": "criteria in the \"Biospecimen and Data Collection\" section",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "The following criteria must also not be present:",
                    "criterion": "the following criteria (unspecified in this line)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with recurrent/refractory PCNSL. Patients with stable disease as their best response to first-line chemotherapy will also come off study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with recurrent/refractory PCNSL",
                    "criterion": "PCNSL disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "recurrent",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with stable disease as their best response to first-line chemotherapy will also come off study",
                    "criterion": "response to first-line chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "best response",
                            "expected_value": "stable disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Criteria for Nivolumab Maintenance Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nivolumab Maintenance Arm",
                    "criterion": "treatment arm",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "Nivolumab Maintenance Arm"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient is unwell or unable to participate in all required study evaluations and procedures",
            "criterions": [
                {
                    "exact_snippets": "The patient is unwell",
                    "criterion": "patient wellness",
                    "requirements": [
                        {
                            "requirement_type": "wellness status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to participate in all required study evaluations and procedures",
                    "criterion": "ability to participate in study evaluations and procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received a live / attenuated vaccine within 30 days of first treatment.",
            "criterions": [
                {
                    "exact_snippets": "received a live / attenuated vaccine within 30 days of first treatment",
                    "criterion": "live/attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": [
                                "live",
                                "attenuated"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient's who are planned to undergo consolidation with autologous HSCT",
            "criterions": [
                {
                    "exact_snippets": "planned to undergo consolidation with autologous HSCT",
                    "criterion": "planned consolidation with autologous HSCT",
                    "requirements": [
                        {
                            "requirement_type": "planned procedure",
                            "expected_value": "consolidation with autologous HSCT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive plasma hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and Reproduction)",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant ... pregnancy is defined as a state of a female after conception until the termination of gestation",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing (lactating)",
                    "criterion": "nursing (lactating) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by a positive plasma hCG laboratory test of > 5 mIU/mL",
                    "criterion": "plasma hCG laboratory test result",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient's who are planned to undergo consolidation with autologous HSCT",
            "criterions": [
                {
                    "exact_snippets": "planned to undergo consolidation with autologous HSCT",
                    "criterion": "planned consolidation with autologous HSCT",
                    "requirements": [
                        {
                            "requirement_type": "treatment plan",
                            "expected_value": "planned consolidation with autologous HSCT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "disease modifying agents",
                                "corticosteroids",
                                "immunosuppressive drugs"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
                    "criterion": "replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "thyroxine",
                                "insulin",
                                "physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency"
                            ]
                        },
                        {
                            "requirement_type": "systemic treatment classification",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests",
            "criterions": [
                {
                    "exact_snippets": "history of active or chronic infection with hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "history of active or chronic infection with ... hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by serologic tests",
                    "criterion": "serologic test for hepatitis B or C",
                    "requirements": [
                        {
                            "requirement_type": "test performed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to safety or study outcomes (per investigator judgment)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is allergic to components of the study drug",
            "criterions": [
                {
                    "exact_snippets": "Patient is allergic to components of the study drug",
                    "criterion": "allergy to components of the study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has an active concurrent malignancy requiring active therapy",
            "criterions": [
                {
                    "exact_snippets": "active concurrent malignancy",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring active therapy",
                    "criterion": "concurrent malignancy therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is known to have an uncontrolled active systemic infection",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled active systemic infection",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous or current treatment with an anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PDL2 agent",
            "criterions": [
                {
                    "exact_snippets": "Previous or current treatment with an anti-CTLA-4",
                    "criterion": "treatment with anti-CTLA-4 agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous or current treatment with an ... anti-PD-1",
                    "criterion": "treatment with anti-PD-1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous or current treatment with an ... anti-PD-L1",
                    "criterion": "treatment with anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous or current treatment with an ... anti-PDL2",
                    "criterion": "treatment with anti-PDL2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}